Document is current
Any future updates will be listed below
-
Authors
Steenholdt, Casper https://orcid.org/0000-0003-3898-4212
Lorentsen, Ruben Due
Henneberg, Jon
Petersen, Pernille Nørgaard
Brynskov, Jørn
-
Funding
Funding for this research was provided by:
Takeda Pharmaceuticals International (IISR-2019-103039)
Odense University Hospital
- License Information
-
More Information
Article History
Accepted: 29 May 2025
First Online: 18 June 2025
Declarations
:
: Open access funding provided by Odense University Hospital. Measurements of vedolizumab and antibodies against vedolizumab were supported by an Investigator Initiated Research grant from Takeda Pharma A/S, a member of the Takeda group of companies (IISR-2019-103039).
: CS: Lectures for Takeda, MSD and Janssen-Cilag; research grant from Takeda. JB: advisory board and/or education from Abbvie, Takeda, Janssen, Bristol Myers and MSD. RDL, PNP, JH: none.
: Study concept and design: CS. Acquisition of data: CS + RDL + PØP + JH. Analysis of data: CS. Interpretation of data: All authors. Drafting of the manuscript: CS. Critical revision of the manuscript: All authors. Final approval: All authors.
: Data are available in the article. Raw data are not publicly available.
: Ethics approval was received from the Ethics Committee (H-16020384) and Danish Data Protection Agency (2012-58-0004).
: Not applicable.
: Not applicable.
: Not applicable.
